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Abstract 
 
One of the most statistically significant loci to result from large-scale GWAS of schizophrenia 
is 10q24.32. However, it is still unclear how this locus is involved in the pathoaetiology of 
schizophrenia. The hypothesis that presynaptic dopamine dysfunction underlies 
schizophrenia is one of the leading theories of the pathophysiology of the disorder. 
Supporting this, molecular imaging studies show evidence for elevated dopamine synthesis 
and release capacity. Thus, altered dopamine function could be a potential mechanism by 
which this genetic variant acts to increase the risk of schizophrenia. 
We therefore tested the hypothesis that the 10q24.32 region confers genetic risk for 
schizophrenia through an effect on striatal dopamine function. To this aim we investigated 
the in vivo relationship between a GWAS schizophrenia-associated SNP within this locus and 
dopamine synthesis capacity measured using [18F]-DOPA PET in healthy controls. 92 healthy 
volunteers underwent [18F]-DOPA PET scans to measure striatal dopamine synthesis 
capacity (indexed as Kicer) and were genotyped for the SNP rs7085104. We found a 
significant association between rs7085104 genotype and striatal Kicer. Our findings indicate 
that the mechanism mediating the 10q24.32 risk locus for schizophrenia could involve 
altered dopaminergic function. Future studies are needed to clarify the neurobiological 
pathway implicated in this association. 
Key words: schizophrenia; 10q24.32; psychosis; dopamine synthesis capacity; PET; striatum; imaging 
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1 Introduction 
 
Large-scale Genome-Wide Association Studies (GWAS) have identified a number of common genetic 
variations conferring risk for schizophrenia in human populations (Pardiñas et al., 2018; Ripke et al., 
2014, 2013, 2011). Nevertheless, it remains challenging to assign the association signal at risk loci 
to specific genes or mechanisms, which is a requirement if genetic findings are to help elucidate the 
pathophysiology of the disorder. In this sense it is important to identify methods to investigate the 
biological pathways linked to risk loci and thus help identify potential pharmacological targets 
(Birnbaum and Weinberger, 2017; Schubert et al., 2014). 
One of the best supported genome-wide significant loci from large-scale GWAS of schizophrenia is 
the 10q24.32 region (Duarte et al., 2016; Pardiñas et al., 2018; Ripke et al., 2014). Potential specific 
molecular mechanisms of genetic risk related to this locus have been recently identified. In 
particular, increased expression of BLOC-1 related complex subunit 7 (BORCS7) and of a novel 
arsenite methyltransferase isoform, namely AS3MTd2d3, have been found in the brains of patients 
with schizophrenia relative to controls (Li et al., 2016b). In the general population, the full isoform 
of arsenite methyltransferase is involved in arsenic metabolism (Sumi and Himeno, 2012), and 
arsenic toxicity has been implicated in central nervous system (CNS) dysfunction (Tyler and Allan, 
2014) and psychosis (Ratnaike, 2003). However, the AS3MTd2d3 isoform lacks arsenite 
methyltransferase activity (Li et al., 2016b); therefore a different, and still unknown, mechanism is 
likely to be implicated in the biological process leading to risk for schizophrenia. 
The hypothesis that dopamine dysfunction underlies schizophrenia is one of the leading theories of 
the pathophysiology of the disorder (Abi-Dargham et al., 2000; Davis et al., 1991; Heinz et al., 2003; 
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Heinz and Schlagenhauf, 2010; Howes et al., 2015, 2012; Howes and Kapur, 2009; Laruelle and Abi-
Dargham, 1999) and is supported by findings from genetic studies of the disorder through genome-
wide significant association at a locus implicating the DRD2 dopamine receptor (Pardiñas et al., 
2018; Ripke et al., 2014). Molecular imaging studies show evidence for presynaptic striatal 
dopamine dysfunction, in particular increased striatal dopamine synthesis and release capacity, in 
patients with schizophrenia (Abi-Dargham et al., 2009; Hietala et al., 1999; Howes et al., 2013, 2009; 
Jauhar et al., 2017a; Kumakura et al., 2007; Meyer-Lindenberg et al., 2002; Mizrahi et al., 2012; Reith 
et al., 1994) with a large effect size on meta-analysis (Cohen d = 0.79) (Howes et al., 2012). 
Moreover, increased dopamine synthesis capacity is also reported in individuals at increased clinical 
risk of schizophrenia (Egerton et al., 2013; Howes et al., 2011a), as well as in first-degree relatives 
of patients with schizophrenia (Huttunen et al., 2008), and linked to transition to the disorder 
(Howes et al., 2011b). Thus, altered dopamine synthesis capacity could be a potential mechanism 
by which genetic variation acts to increase risk of schizophrenia. 
Our study aimed to test the hypothesis that the association signal at the 10q24.32 locus confers 
genetic risk for schizophrenia through an effect on striatal dopamine function. We therefore 
investigated the in vivo relationship between the GWAS schizophrenia-associated SNP rs7085104 
(the top expression quantitative trait locus (eQTL) for AS3MT and BORCS7 (Li et al., 2016b)) and 
dopamine synthesis capacity, measured using [18F]-DOPA positron emission tomography (PET) in 
healthy controls. We hypothesised that carriers of the rs7085104 risk allele (A) would show 
increased striatal dopamine synthesis capacity relative to controls who did not carry the risk allele. 
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2 Methods 
2.1 Participants 
We studied 92 healthy volunteers (demographics in Table 1). Inclusion criteria were: minimum age 
18 years, good physical health with no history of major medical condition and capacity to give 
written informed consent. Exclusion criteria were: history of significant head trauma, history of 
neurological disorder, presence of any significant medical disorder or treatment, pregnancy or 
breastfeeding, a diagnosis of past or current psychiatric disorders using the Structured Clinical 
Interview for DSM-IV (SR et al., 1996) including alcohol or any other substance dependence or 
abuse, a family history of any psychotic disorder in first- or second- degree relatives.  PET data from 
some participants have been included in previous publications (Bloomfield et al., 2014a, 2014b; 
Dahoun et al., 2018; Froudist-Walsh et al., 2017; Jauhar et al., 2017b). 
2.2 SNP Selection and Genotype determination 
We chose rs7085104 as the sole polymorphism of interest for this study given cumulative evidence 
for its importance in the 10q24 associated region: (i) a recent finding implicating it as the top SNP 
eQTL for AS3MT and BORCS7 (Li et al., 2016b), (ii) it was the index SNP at this locus in previous 
schizophrenia GWAS association (Ripke et al., 2013) and (iii) in a recent genome-wide methylation 
study rs7085104 was found to be a methylation QTL in human fetal brain for AS3MT (Hannon et al., 
2015). 
DNA was extracted from whole blood samples or cheek swabs using standard procedures (Freeman 
et al., 2003). Genotyping was performed at Cardiff University, using HumanCore Exome 1.1 arrays 
(“Psych-chip”, Illumina, San Diego, California, USA). Genotype quality control (QC) was performed 
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according to standard parameters (Anderson et al., 2010). The variant of interest for our analysis, 
rs7085104, was directly genotyped and passed QC in all the subjects. 
2.3 Population structure 
The top 10 principal components of the sample were generated using PC-AiR (Conomos et al., 2015) 
on the full set of genotypes, and included as covariates of no interest in all the analyses, in order to 
correct for population stratification. 
Moreover, to confirm the robustness of the findings, the analyses were repeated in a sub-group of 
individuals of European ancestry. To this aim, each individual was assigned to a cluster (European, 
African, Asian) on the basis of their ancestry score (threshold for the attribution to a specific cluster: 
0.7). Ancestry scores were calculated using ADMIXTURE (Alexander et al., 2009) (Version 1.3.0) with 
the Human Genome Diversity Panel (HGPD-CEPH) (Li et al., 2008) as a reference. 
2.4 PET scanning 
[18F]-DOPA PET scans were used to measure striatal dopamine synthesis capacity (indexed as the 
influx rate constant Kicer). 
2.4.1 Image acquisition 
Dynamic scans were acquired in three-dimensional mode (transaxial resolution of ~5 mm full width 
at half maximum ((NEMA), 2007) using three different PET scanners: one was a ECAT HR+ 962 PET 
scanner (CTI/Siemens, Knoxville, Tennessee) while the other two were Siemens Biograph HiRez XVI 
PET-CT scanners (Siemens Healthcare, Erlangen, Germany). Subjects were asked to refrain from 
eating and drinking (except water) for at least 12 hours before the scans. One hour before the scan, 
all participants received 400 mg entacapone, a peripheral catechol-o-methyl-transferase inhibitor 
which decreases the formation of radiolabelled metabolites that may cross the blood–brain barrier 
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(Cumming et al., 1993; Guttman et al., 1993), and 150 mg carbidopa, a peripheral aromatic acid 
decarboxylase inhibitor which reduces the peripheral metabolism of the tracer (Garnett et al., 
1983). Approximately 150 MBq of radioactive [18F]-DOPA was administered by intravenous injection 
followed by 95 minutes of dynamic PET scan. PET data were reconstructed using filterback 
projection and corrected for tissue attenuation and scatter (full details are reported in (Bloomfield 
et al., 2014a, 2014b; Froudist-Walsh et al., 2017; Jauhar et al., 2017b)). 
2.4.2 Analysis of PET data  
PET image analysis was performed as previously described (Dahoun et al., 2018). In summary, 
frames were realigned to a single reference frame, employing a mutual information algorithm 
(Studholme et al., 1996; Turkheimer et al., 1999). The transformation parameters were then applied 
to the corresponding attenuated-corrected dynamic images, creating a movement-corrected 
dynamic image, which was used in the analysis. Realigned frames were then summated to create 
an individual motion-corrected reference map for the brain tissue segmentation. The striatum was 
sub-divided into sub-regions as previously described (Howes et al., 2009; Martinez et al., 2003) to 
create a Region of Interest (ROI) map (Egerton et al., 2010). SPM8 
(http://www.fil.ion.ucl.ac.uk/spm) was used to normalize a tracer-specific ([18F]-DOPA) template 
together with the ROI map to each individual PET summation image (Howes et al., 2009). The striatal 
influx constant (Kicer) was calculated relative to uptake in the reference region using a graphical 
approach adapted for a reference tissue input function (Howes et al., 2009). To control for effects 
of scanner model, PET scanners were included as covariates of no interest in all analyses. 
2.5 Statistical analysis 
ANOVA and χ2 tests were used to compare demographics age and gender as functions of rs7085104 
genotype. ANCOVA analyses were performed to explore the correlation between genotype and 
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dopamine synthesis capacity (fixed factor: rs7085104 genotype [three groups: GG, GA, AA, 
dependent variable: Kicer, covariates of no interest: age, gender, scanner, top 10 genetic principal 
components). Exploratory analyses were conducted using associative striatum, limbic striatum and 
sensorimotor striatum Kicer as dependent variables. All these were performed in SPSS (IBM Corp. 
Released 2016. IBM SPSS Statistics for Mac, Version 24.0.0.1 Armonk, NY: IBM Corp.). GraphPad 
Prism 7.02 (http://www.graphpad.com/) was used to plot the main results. 
The R package RobustSNP (So and Sham, 2011) was used to confirm the genetic model suggested 
by the LSD post hoc analysis. The robust tests were performed including the same covariates of no 
interest used for the ANCOVAs.  
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3 Results 
Demographic (± SD) and Kicer values included are reported in Table 1. 
Genotype groups were in Hardy-Weinberg Equilibrium (X2= 0.16, p= 0.69) and did not differ in terms 
of age (p= 0.22), sex (X2= 0.86, p= 0.65), PET scanner (X2= 5.66, p= 0.23) or tobacco smoking status 
(X2= 0.94, p= 0.62). 
The frequency of the schizophrenia risk allele in our sample approximated that reported in the 
public NCBI database dbSNP (Sherry, 2001). Specifically, the risk allele (A) of rs7085104 had a 
reported frequency of 0.62 in the latter, while the frequency for our sample was 0.69. 
We found a significant association between rs7085104 genotype and whole striatal Kicer (F(2,76)= 
4.660, p= 0.012) [Fig. 1]. LSD post-hoc analyses showed that risk allele carriers had significantly 
elevated Kicer compared to subjects with the genotype GG (GA vs GG, p= 0.003; GA vs AA, p= 0.275; 
AA vs GG, p= 0.020, Hedges’ g= 0.957), suggesting a dominant effect of A alleles. The RobustSNP 
association test confirmed the dominant model for this association (ZDominant Model= 2.337, pDominant 
Model= 0.019). 
The exploratory analyses in the striatal subdivisions revealed an effect of genotype on dopamine 
synthesis capacity for all the regions. Specifically, we found an effect of rs7085104 genotype on 
associative Kicer (F(2,76)= 4.075, p= 0.021; LSD post-hoc contrasts: GA vs GG, p= 0.006; GA vs AA, p= 
0.424; AA vs GG, p= 0.020) [Fig. 2a], limbic Kicer (F(2,76)= 5.453, p= 0.006; LSD post-hoc contrasts: 
GA vs GG, p= 0.001; GA vs AA, p= 0.406; AA vs GG, p= 0.007) [Fig. 2b], and sensorimotor Kicer (F(2,76)= 
4.100, p= 0.020; LSD post-hoc contrasts: GA vs GG, p= 0.008; GA vs AA, p= 0.126; AA vs GG, p= 0.071) 
[Fig. 2c]. RobustSNP association tests confirmed the dominant effect of A alleles on dopamine 
synthesis capacity for all the striatal subdivisions (associative Kicer : ZDominant Model= 2.217, pDominant Model= 
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0.0266; limbic Kicer : ZDominant Model= 2.480, pDominant Model= 0.013; sensorimotor Kicer : ZDominant Model= 2.345, 
pDominant Model= 0.019). 
The sensitivity analyses performed in the sub-group of individuals of European Ancestry confirmed 
the association of rs7085104 genotype with whole striatal Kicer (F(2,48)= 6.102, p= 0.004) and all the 
striatal subdivisions: associative Kicer (F(2,48)= 4.835, p= 0.012); limbic Kicer (F(2,48)= 6.935, p= 
0.002); and sensorimotor Kicer (F(2,48)= 6.091, p= 0.004). 
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4 Discussion 
 
We report for the first time an in vivo association between the schizophrenia-associated SNP 
rs7085104 and striatal dopamine synthesis capacity. Specifically, we found that the rs7085104 risk 
allele (A) carriers show higher striatal Kicer than the subjects homozygous for the G allele. It is not 
clear at present whether the possible dominant effect we have detected on dopamine synthesis 
capacity matches the observed effect of this SNP as a schizophrenia risk allele, since the latter has 
at the moment only been assessed by GWAS based on simple additive models (Pardiñas et al., 2018; 
Ripke et al., 2014, 2013). In order to resolve this, explicit modelling of dominance effects in large-
scale schizophrenia samples would have to be performed, as has been explored in other psychiatric 
conditions (Leblond et al., 2019; Van der Auwera et al., 2018). At the moment, dominant effects are 
not currently considered to explain much of the variance of human complex traits in general, though 
they have been shown to exist at some particular loci (Zhu et al., 2015). 
These results offer new insights into the biological mechanisms that could underlie the association 
of the locus 10q24.32 with schizophrenia. A genetic risk variant on chromosome 10q24.32 has 
recently been demonstrated to correlate with the expression of the gene AS3MT (Duarte et al., 
2016). AS3MT codes for an arsenic methyltransferase (Lin et al., 2002; Sumi and Himeno, 2012). 
Since arsenic can result in CNS toxicity and neurological sequelae, including the development of 
psychosis (Ratnaike, 2003; Tyler and Allan, 2014), it has been speculated that dysregulation of 
arsenic metabolism mediates the relationship between this genetic locus and schizophrenia. 
However, Li and colleagues (Li et al., 2014) have demonstrated that the top GWAS SNP for this locus 
is not associated with the full-length isoform of the AS3MT transcript (AS3MTfull) but with the 
isoform AS3MTd2d3, which lacks arsenite methyltransferase activity. Therefore, alterations in arsenic 
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metabolism may not explain the association between rs7085104 and schizophrenia. Our data 
suggest that the dopaminergic pathway is involved in this association. 
The rs7085104 SNP might impact dopamine synthesis capacity through its association with the 
expression of BORCS7 (Li et al., 2016b). Specifically, the risk genotype (A) is associated with 
upregulation of this protein, which forms one of the subunits of BLOC-one-related complex (BORC). 
BORC in turn makes up subunits of lysosome-related organelles complex 1 (BLOC-1), which has been 
shown to be involved in modulation of dopaminergic neurotransmission (Iizuka et al., 2007; Nagai 
et al., 2010). 
There is accumulating evidence to support the longstanding neurodevelopmental hypothesis of 
adult-onset psychiatric disorders and in particular schizophrenia (Birnbaum et al., 2015; Howes and 
Murray, 2014; Jaffe et al., 2014; Weinberger, 1987). Therefore, it is noteworthy that the expression 
of AS3MTd2d3 and BORCS7 is up-regulated in early neuronal differentiation (Li et al., 2016b). In 
consideration of the fact that human dopaminergic innervation is also present in the early phases 
of neurodevelopment (Money and Stanwood, 2013; Zecevic and Verney, 1995), it can be speculated 
that the genetic variant examined in our study exerts its effect on the dopaminergic system early in 
the neurodevelopment, increasing risk for schizophrenia (Hannon et al., 2015). 
Our study was conducted in healthy subjects; therefore, future work should focus on patients with 
schizophrenia and other major psychiatric disorders. Supporting this assertion of broader 
implications of 10q24.32 in serious mental illness, rs7085104 and two other SNPs in linkage 
disequilibrium (rs7914558 (D’= 0.956; r2 = 0.689 in Europeans) and rs11191580 (D’= 1; r2= 0.178 in 
Europeans)) within this chromosomal region are also associated with bipolar disorder, major 
depressive disorder, schizophrenia, autism spectrum disorder, and attention deficit-hyperactivity 
disorder (Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013; Li et al., 2016a; 
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Psychiatric GWAS Consortium Bipolar Disorder Working Group et al., 2011; Ripke et al., 2011). In 
this context, it is noteworthy that expression of AS3MTd2d3 is elevated in patients not only with 
schizophrenia but also major depression when compared with healthy subjects. Dopamine 
dysregulation, namely elevated dopamine synthesis capacity, has been demonstrated in patients 
with bipolar disorder with psychosis as well as in schizophrenia (Jauhar et al., 2017a). It could be 
speculated that the mediator of the association of this locus with major psychiatric disorders is the 
dopaminergic system. 
Strengths and Limitations 
Since there is evidence of increased striatal dopamine synthesis capacity in schizophrenia (Howes 
et al., 2012), the increased striatal dopamine synthesis capacity of the risk allele carriers could 
explain the association of this genetic variant with schizophrenia (Ripke et al., 2014). 
However, it should be considered that association does not necessarily imply causality. Pre-clinical 
studies are needed to clarify the mechanism that links the genetic risk given by polymorphisms 
within 10q24.32-33 with dysregulation in the dopaminergic system. Moreover, in consideration of 
the small proportion of subjects with the genotype GG for the SNP rs7085104 and of the fact that 
some imaging studies based on a candidate gene approach have shown contradictory findings 
(Bogdan et al., 2017), replications with a higher number of subjects are needed. Nevertheless, to 
our knowledge, this study is one of the largest PET studies of association of a genetic variant with 
dopamine function  (Dahoun et al., 2018; Gluskin and Mickey, 2016; Laakso et al., 2005; Shumay et 
al., 2017; Wiers et al., 2017; Wu et al., 2012). 
We note that, for the SNP described herein, the allele associated with increased schizophrenia risk 
is the most common allele in the general population. Whilst risk alleles for disorders are generally 
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minor alleles (Kido et al., 2018), this is not always the case and several risk alleles identified by 
GWAS have frequencies higher than 50% in the general population (Cross-Disorder Group of the 
Psychiatric Genomics Consortium, 2013; Mulle, 2012). This is in line with the evidence that 
schizophrenia is a polygenic disorder; and many common variants contribute to risk and protection, 
each with small effects (Weinberger, 2019). These small effects have likely enabled a proportion of 
these risk variants to become highly represented in the general population as a consequence of 
genetic drift or balancing selection (Owen et al., 2016; Pardiñas et al., 2018). 
A relevant limitation was the use of data from three different PET scanners. However, to control for 
this, PET scanners were included as covariates of no interest in all the analyses. Anyway, there was 
no difference in the genotype distribution across the three scanners. Furthermore, some 
participants were smokers; however, groups did not differ for smoking status and dopamine 
synthesis capacity is not altered in moderate smokers (Bloomfield et al., 2014a); and it is not clear 
if even heavy smoking has a significant effect on dopamine synthesis capacity (Ashok et al., 2019). 
Our sample was not homogeneous for ethnicity, thus genetic principal components were included 
as covariates in all the analyses, in order to correct for population stratification. However, a recent 
GWAS has shown an association of common genetic variants within the locus 10q24.32 with 
schizophrenia in the Han Chinese population (Yu et al., 2016). Moreover, a variable number tandem 
repeat (VNTR) in the first exon of AS3MT is associated with AS3MTd2d3 mRNA expression not only in 
Caucasian subjects but also in African Americans (Li et al., 2014). This would indicate that the 
association of this locus with schizophrenia is ethnicity-independent. 
Implications 
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Studies such as this can help move from a genomic region of association to highlighting potential 
mechanisms through which candidate SNPs within the region are acting to increase the risk for 
schizophrenia. Our study can be considered a step towards translation of one of the most 
statistically significant findings in the genetics of schizophrenia, the association of the locus 
10q24.32, towards the identification of novel treatment targets in line with recent proposals 
(Birnbaum & Weinberger, 2017; Schubert et al., 2014). 
The modest effect size of the association between rs7085104 and dopamine synthesis capacity is in 
line with the fact that the risk for schizophrenia conferred by each of the schizophrenia GWAS-
significant loci is relatively small (Ripke et al., 2014). In this regard, the contribution of this SNP to 
the variation in the striatal Kicer - as can be deduced from the difference between the subjects 
homozygous for the risk variant and the individuals homozygous for the G allele (Hedges’ g= 0.957) 
- is in line with the effect size of the association of AS3MTd2d3 expression with diagnosis of 
schizophrenia (effect size= 0.813 (Li et al., 2016b)). However, given the modest sample size of G 
homozygotes in our study, our effect size estimate should be considered as preliminary and 
warrants replication. Moreover, in view of the fact the risk allele is common in the general 
population, it is important to note that other genetic and environmental factors, such as 
psychosocial stressors, cannabis use, and obstetric complications are likely to combine to lead to 
schizophrenia (Birnbaum and Weinberger, 2017; Howes et al., 2017). 
4.1 Conclusions 
The results from the present work indicate that the mechanism mediating the 10q24.32 risk locus 
for schizophrenia could involve altered dopaminergic function. Future studies are needed to clarify 
the neurobiological pathway implicated in this association.  
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Table 1 
Demographic characteristics of the sample 
 
 
Figure 1 
 
Effect of AS3MT rs7085104 on whole striatum Ki
cer 
 
Figure 2 
Exploratory analyses: effect of AS3MT rs7085104 on Ki
cer  in the different striatal subdivisions 
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Table 1 
Demographic characteristics of the sample 
 
 
 
AA GA GG Total 
N 43 41 8 92 
Age (yr ± SD) 28.28 ± 8.34 31.17 ± 8.46 32.50 ± 12.47 29.93 ± 8.84 
Gender (male/female) 26/17 21/20 5/3 52/40 
Ancestry cluster 
(EUR/AFR/ASI/other) 
31/9/0/3 27/7/2/5 6/0/1/1 64/16/3/9 
PET scanner (scanner 1/ 
scanner 2/ scanner 3) 
18/20/5 16/13/12 3/2/3 37/35/20 
Tobacco smoking status (non-
smoker/smoker) 
36/7 31/10 6/2 73/19 
K
i
cer
 (1/min) whole striatum (± 
SD)  
0.013 ± 0.001 0.013 ± 0.001 0.012 ± 0.001 0.013 ± 0.001 
K
i
cer
 (1/min) associative 
striatum (± SD) 
 
0.013 ± 0.001 0.013 ± 0.001 0.012 ± 0.001 0.013 ± 0.001 
K
i
cer
 (1/min) limbic striatum (± 
SD) 
 
0.013 ± 0.001 0.013 ± 0.001 0.012 ± 0.001 0.013 ± 0.001 
K
i
cer
  (1/min) sensorimotor 
striatum (± SD) 
 
0.013 ± 0.001 0.014 ± 0.002 0.012 ± 0.001 0.013 ± 0.001 


